Targeting EGFR/HER2 heterodimerization with a novel anti-HER2 domain II/III antibody
Xiaojie Yu(University of Southampton), Bohua Li(Second Military Medical University), Beibei Liang(Jiading District Central Hospital), Huafeng Wei(Chinese PLA General Hospital), Changhai Lei(Second Military Medical University), Chao Wang(Tianjin Medical University), Yajun Zhang(Second Military Medical University), Lingfei Wang(Broad Institute), Bo Zhou(Tongji Hospital), Yanchun Meng(Fudan University Shanghai Cancer Center), Yang Yang(Second Military Medical University), Huajing Wang(Shanghai University of Medicine and Health Sciences), Yafeng Shen(Second Military Medical University), Shi Hu(Second Military Medical University)
Cited by 23
Related Papers
CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
|Nature Communications|2019|484
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
|Nature Communications|2020|432
QRICH1 dictates the outcome of ER stress through transcriptional control of proteostasis
|Science|2020|149
Ascites-derived IL-6 and IL-10 synergistically expand CD14+HLA-DR-/low myeloid-derived suppressor cells in ovarian cancer patients
|Oncotarget|2017|110
Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways
|International Journal of Oncology|2016|109